SEVENFACT® Study for Hemophilia Bleeding Events is a research project for people aged 12 and older with Hemophilia A or B, who have inhibitors. Hemophilia is a condition where blood doesn't clot properly, causing excessive bleeding. Inhibitors are substances that make treating hemophilia harder. The study tests SEVENFACT®, a treatment that helps stop bleeding. Participants might already be on medicines like emicizumab to prevent bleeding, or they might not be on any prevention treatment. The main goal is to see if SEVENFACT® is safe for them.
The study lasts up to 2 years. Approximately 28 to 55 people will join, with 100 bleeding events targeted for treatment. Participants will share their experiences using a mobile app or paper diary. Researchers will look at any side effects or reactions participants have during the study.
- The study lasts up to 2 years.
- Participants must be 12 years or older and have Hemophilia A or B with inhibitors.
- Participants may need to record their experiences using a mobile app or paper diary.